Fate Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Fate Therapeutics (NASDAQ: FATE) announced its participation in several upcoming investor conferences. The key events include Cowen’s 6th Annual IO Next Summit on November 11, 2022, Jefferies London Healthcare Conference on November 16, 2022, and Piper Sandler 34th Annual Healthcare Conference on November 29, 2022. Presentations will be available via live webcasts on the Company’s website, with archived recordings shortly after the events. Fate Therapeutics focuses on developing innovative cellular immunotherapies for cancer patients using its proprietary iPSC platform.

SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the following upcoming investor conferences:

• Cowen’s 6th Annual IO Next Summit available on demand on Friday, November 11, 2022 at 2:10 PM ET
• Jefferies London Healthcare Conference on Wednesday, November 16, 2022 at 12:55 PM GMT, 7:55 AM ET, in London, United Kingdom
• Piper Sandler 34^th Annual Healthcare Conference on Tuesday, November 29, 2022 at 12:00 PM ET in New York, New York
  

A live webcast, if recorded, of each presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina@sternir.com

FAQ

What are the upcoming investor conferences for Fate Therapeutics?

Fate Therapeutics will present at Cowen’s 6th Annual IO Next Summit on November 11, Jefferies London Healthcare Conference on November 16, and Piper Sandler 34th Annual Healthcare Conference on November 29, 2022.

When and where is the Jefferies London Healthcare Conference?

The Jefferies London Healthcare Conference will take place on November 16, 2022, at 12:55 PM GMT (7:55 AM ET) in London, United Kingdom.

How can I access the presentations from Fate Therapeutics' conferences?

Presentations will be available via live webcasts on Fate Therapeutics' website under the 'Events & Presentations' section, with archived recordings accessible shortly after.

What is the focus of Fate Therapeutics?

Fate Therapeutics is dedicated to developing programmed cellular immunotherapies for cancer patients, utilizing a proprietary induced pluripotent stem cell (iPSC) platform.

What is Fate Therapeutics' stock symbol?

Fate Therapeutics is traded under the stock symbol 'FATE' on NASDAQ.